



Correction: Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after

Carme Miret^{1,2,3} · Miren Orive^{4,6,7,8} · Maria Sala^{2,7} · Susana García-Gutiérrez^{5,6,7,8} · Cristina Sarasqueta^{7,8,9} · Maria Jose Legarreta^{5,6,7,8} · Maximino Redondo^{7,8,10} · Amado Rivero¹¹ · Xavier Castells^{2,7} · José M. Quintana^{5,6,7,8} · Olatz Garin^{3,12} · Montse Ferrer^{12,13,14} on behalf of the REDISSEC-CaMISS Group

Published online: 8 March 2024
© The Author(s) 2024

Correction to:

Quality of Life Research (2023) 32:989–1003
<https://doi.org/10.1007/s11136-022-03327-4>

In the original publication of the article, the authors realized that the scores of two dimensions of the EORTC QLQ BR23 (Sexual Function and Sexual Enjoyment) were wrongly

reversed while preparing the tables. This mistake affects two lines (Sexual Function and Sexual Enjoyment) of Table 4 and Supplementary Table (1.3.2, 1.3.3, 2.3.2 and 2.3.3). The correct version of Table 4 and the supplementary information are provided in this correction. The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s11136-022-03327-4>.

✉ Montse Ferrer
mferrer@imim.es

¹ Department of Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Universitat Autònoma de Barcelona (UAB), 08193, Bellaterra, Barcelona, Spain

² Preventive Medicine and Public Health Training Unit PSMar-UPF-ASPB, Parc de Salut Mar, Agència de Salut Pública de Barcelona, i Universitat Pompeu Fabra, Barcelona, Spain

³ IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

⁴ Departamento Psicología Social, Facultad Farmacia, UPV/EHU, Vitoria-Gasteiz, Araba, Spain

⁵ Osakidetza Basque Health Service, Research Unit, Galdakao-Usansolo University Hospital, Galdakao, Bizkai, Spain

⁶ KRONIKGUNE-Institute for Health Service Research, Barakaldo, Bizkaia, Spain

⁷ Health Services Research on Chronic Patients Network (REDISSEC), Galdakao, Bizkaia, Spain

⁸ Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Madrid, Spain

⁹ Biodonostia Health Research Institute, Donostia University Hospital, Donostia, Gipuzkoa, Spain

¹⁰ Research and Innovation Unit, Hospital Costa del Sol, Marbella, Spain

¹¹ Servicio de Evaluación y Planificación del Servicio Canario de la Salud (SESCS), Tenerife, Spain

¹² Health Services Research Group, IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader 88, 08003 Barcelona, Spain

¹³ CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

¹⁴ Departament de Medicina i Ciències de la Vida, Universitat Pompeu Fabra (UPF), Barcelona, Spain

Table 4 Mean scores and standard deviations of EORTC QLQ-BR-23 according to age, Charlson Comorbidity Index, and stage

	All	Age			Comorbidity index		Tumor stage				p value*		
		<40	40–65	>65	0	≥1	0	I	II	III			
												p value*	p value*
At diagnosis													
Body Image	92.3 (16.7)	87.5 (20.8)	92.0 (17.0)	94.5 (14.4)	0.003	92.4 (16.3)	92.1 (18.4)	0.779	94.2 (12.6)	92.6 (16.7)	91.9 (17.2)	89.8 (19.8)	0.258
Sexual Function	23.5 (26.1)	31.3 (27.1)	27.4 (26.6)	10.6 (19.2)	<0.001	24.9 (25.8)	18.2 (26.5)	<0.001	24.7 (26.5)	24.9 (26.1)	21.1 (25.4)	21.8 (28.3)	0.126
Sexual enjoy	54.6 (29.1)	59.4 (32.1)	56.2 (28.8)	42.5 (26.1)	<0.001	55.3 (28.9)	50.5 (29.9)	0.140	54.5 (26.6)	54.8 (28.3)	53.6 (29.7)	57 (36.0)	0.913
Future perspective	45.9 (31.9)	36.4 (32.0)	45.7 (31.7)	48.8 (32.2)	0.009	45.8 (31.3)	46.3 (34.2)	0.822	50.3 (29.9)	45.8 (32.1)	46.4 (32.4)	39.2 (31.3)	0.090
Systemic therapy effects	12.5 (13.9)	11.5 (13.9)	12.7 (14.4)	12.4 (12.7)	0.764	12.2 (13.8)	13.6 (14.3)	0.169	12.6 (13.5)	11.8 (13.2)	13.2 (14.8)	14.4 (16.2)	0.235
Breast symptoms	13.2 (16.9)	19.2 (20.4)	13.4 (16.9)	11.1 (15.8)	0.001	13.7 (17.2)	11.0 (15.6)	0.021	13.4 (17.2)	12.5 (17.2)	14.4 (16.7)	12.9 (15.8)	0.342
Arm symptoms	8.7 (15.6)	6.4 (12.5)	8.4 (14.7)	10.0 (18.3)	0.127	8.2 (14.7)	11.0 (18.5)	0.011	7.8 (14.0)	8.4 (15.5)	9.6 (15.8)	8.6 (17.2)	0.592
Upset hair loss	24.0 (31.6)	12.3 (27.7)	25.6 (33.2)	23.6 (27.7)	0.223	23.5 (31.4)	26.7 (33.1)	0.564	11.1 (18.5)	22.9 (32.8)	28.6 (32.5)	33.3 (31.2)	0.053
At 2-year follow-up													
Body Image	84.6 (24.6)	79.7 (28.6)	82.9 (25.8)	88.8 (21.0)	0.001	84.6 (24.7)	84.7 (24.4)	0.956	90.1 (18.3)	86.7 (22.4)	81.4 (27.0)	73.5 (33.7)	<0.001
Sexual Function	20.9 (23.5)	29.5 (21.0)	25 (24.1)	9.9 (17.9)	<0.001	22.4 (24.0)	15.4 (21.0)	<0.001	23.8 (24.1)	21.7 (24.3)	18.9 (22.5)	19 (19.8)	0.163
Sexual enjoy	50.3 (27.8)	62.8 (23.7)	53.2 (27.0)	34.3 (27.1)	<0.001	51.3 (28.1)	45.6 (26.2)	0.070	52.8 (26.3)	51.3 (29.2)	48.2 (27.1)	47 (22.6)	0.518
Future perspective	59.5 (32.1)	55.9 (37.4)	57.1 (31.9)	65.0 (31.4)	0.001	59.2 (31.9)	60.6 (33.0)	0.557	66.4 (29.3)	59.6 (31.6)	59.1 (32.4)	48.4 (36.9)	0.003
Systemic therapy effects	18.3 (16.5)	12.2 (11.1)	18.9 (16.8)	17.9 (16.1)	0.056	17.7 (16.3)	20.7 (17.3)	0.014	16.6 (15.4)	17.8 (15.8)	19.3 (17.8)	21.1 (17.8)	0.171
Breast symptoms	16.0 (17.8)	17.4 (19.5)	17.4 (18.0)	13.0 (16.9)	0.001	15.8 (16.8)	16.6 (21.0)	0.572	15.0 (18.5)	16.0 (17.0)	16.1 (18.7)	17.2 (18.5)	0.859
Arm symptoms	15.7 (20.3)	9.5 (15.0)	16.2 (20.3)	15.5 (20.8)	0.157	15.0 (19.5)	18.2 (23.0)	0.035	12.0 (18.0)	14.2 (19.4)	18.2 (21.0)	22.8 (24.8)	<0.001
Upset hair loss	31.1 (33.7)	13.9 (30.0)	32.0 (33.4)	31.2 (34.3)	0.192	29.4 (32.6)	36.9 (36.7)	0.058	22.0 (26.8)	29.8 (33.4)	34.4 (34.5)	42.0 (40.5)	0.066

*EORTC QLQ-BR-23 differences according to age, comorbidity and stage were tested with ANOVA

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s11136-024-03628-w>.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.